Related Experiment Video
Updated: May 28, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction
Sharanya M Kousik1, Steven M Graves, T Celeste Napier
1Department of Pharmacology and the Center for Compulsive Behaviors and Addiction, Rush University, Robert H. and Terri Cohn Research Building, 1735 West Harrison Street, Chicago, IL 60612, USA. sharanya_m_kousik@rush.edu
Abstract:
Methamphetamine (meth) is a potent psychostimulant known to cause neurotoxicity. Clinical reports suggest meth abuse is a risk factor for Parkinson's disease. We investigated changes in the blood-brain barrier and cerebral vasculature as a mechanism underlying this risk in rats treated acutely and trained to self-administer meth. We observed blood-brain barrier leakage in rats treated acutely with meth. Hypoperfusion in the striatum was detected with acute and chronic meth treatment and was associated with hypoxia. This was correlated with reductions in striatal tyrosine hydroxylase in rats trained to self-administer meth. These findings suggest a new mechanism of meth-induced neurotoxicity involving striatal vasoconstriction resulting in hypoxia and dopamine reductions leading to an increased risk for Parkinson's disease for meth abusers.
Insights
Methamphetamine abuse may increase Parkinson's disease risk by damaging the blood-brain barrier and reducing blood flow to the brain, causing dopamine neuron loss. This neurotoxic mechanism involves hypoxia and striatal vasoconstriction.
Area of Science:
- Neuroscience
- Toxicology
- Neurology
Background:
- Methamphetamine (meth) is a psychostimulant linked to neurotoxicity.
- Clinical observations suggest a correlation between meth abuse and an increased risk of Parkinson's disease.
Purpose of the Study:
- To investigate the potential mechanisms by which methamphetamine abuse may increase the risk of Parkinson's disease.
- To examine changes in the blood-brain barrier and cerebral vasculature following methamphetamine exposure in a rat model.
Main Methods:
- Rats were administered methamphetamine acutely and trained to self-administer the drug.
- Blood-brain barrier integrity was assessed.
- Cerebral blood flow in the striatum was measured using imaging techniques.
- Hypoxia and dopamine-related markers (tyrosine hydroxylase) in the striatum were evaluated.
Main Results:
- Acute methamphetamine treatment led to observable blood-brain barrier leakage.
- Both acute and chronic methamphetamine exposure resulted in hypoperfusion (reduced blood flow) in the striatum.
- Striatal hypoperfusion was associated with hypoxia (oxygen deficiency).
- Methamphetamine self-administration correlated with reduced levels of striatal tyrosine hydroxylase, a marker for dopamine neurons.
Conclusions:
- Methamphetamine-induced neurotoxicity may involve damage to the blood-brain barrier and reduced cerebral blood flow.
- Striatal vasoconstriction leading to hypoxia and subsequent dopamine neuron damage is a potential mechanism linking meth abuse to Parkinson's disease risk.
- These findings highlight a novel pathway for methamphetamine's neurotoxic effects relevant to neurodegenerative disorders.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Drug Abuse and Addiction: Pharmacological Phenomena

